Scroll Top

ADCs a new era in myeloma therapy

ADC_A new era in myeloma therapy_Logo

Independent symposium at the 9th World Congress on Controversies in Multiple Myeloma (COMy)

Publication date: May 2023. Please note that only the live symposium was accredited by EBAH.

Share your feedback: complete a short evaluation here

Chaired by Mohamad Mohty, featuring Jean-Luc Harousseau, María-Victoria Mateos and Rakesh Popat, this 1 hour 15 minute hybrid symposium focused on providing an overview of the historic milestones for multiple myeloma therapy, before focusing on one of the most important topics in the field: the issue of sequencing agents. Finally, updates on recent data on ADCs for relapsed/refractory patients were discussed, together with strategies for managing adverse events.

Learning objectives

After viewing the webcast, you will be able to:

  • Describe the therapeutic changes in the treatment landscape of MM and the advantages brought by new immunotherapy agents
  • Discuss sequencing strategies and factors influencing treatment selection for subsequent treatment lines
  • Analyze available data on ADCs in relapsed MM and strategies to manage AEs associated with these agents


  • Welcome and introduction
  • From alkylating agents to immunotherapy: 50 years of progress
  • Sequencing immunotherapies: where do we stand?
  • ADCs for relapsed/refractory myeloma
  • Discussion and Q&A
  • Close


Mohamad Mohty

Sorbonne University, France

Dr Mohamad Mohty is a Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France. He obtained his medical degree from the University of Montpellier, France, and PhD from the University of Marseille, France. He is also head of a translational research team (Inserm) at the Saint-Antoine Research Centre in Paris.

Dr Mohty is the past president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukemia Working Party of the EBMT. He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and board member of the EBMT and the Intergroupe Francophone du Myelome (IFM).

In addition to publishing more than 900 peer-reviewed articles in the field of stem cell transplantation, leukemia, and myeloma, Dr Mohty also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International.

Honoraria: Adaptive Biotechnologies, Amgen, Astellas, BMS, GSK, Janssen, Jazz, Novartis, Pfizer, Sanofi, Stemline, Takeda
Research funding: Janssen, Sanofi

Jean-Luc Harousseau
Institut de cancerologie de l’ouest, France

Jean-Luc Harousseau is Professor of Hematology at the University of Nantes in France. He was Chairman of the French National Authority for Health (HAS) from February 2011 to January 2016 and Chair of its Economic and Public Health Evaluation Committee from February 2014 to January 2016. He headed the Department of Clinical Haematology in Nantes University Hospital for 24 years and was Director of the Cancer Center René Gauducheau in Nantes from October 2008 to January 2011.

In his previous positions, he has been a member of the Scientific Advisory Board of the French National Cancer Institute and President of the Clinical Research in Oncology National Committee from October 2008 to January 2011.

His areas of research interest concern the therapy of acute myeloid leukemia and for the last thirty years Multiple Myeloma. He received the 2005 Waldenström Award and the 2009 Robert Kyle Award for his scientific contribution in the field of Multiple Myeloma. Professor Harousseau has contributed to more than 500 peer-reviewed publications.

None to declare

María-Victoria Mateos
University Hospital of Salamanca, Spain

Dr. María-Victoria Mateos, MD, PhD, is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit.

She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials especially in the setting of transplant ineligible and smouldering myeloma and these trials have profoundly influenced current options for the management of these patient populations.

She has published over 350 papers in international journals with a H index of 96 and 74 since 2015.

Honoraria derived from lectures and participation in advisory boards from: AbbVie, Adaptive, Amgen, bluebird bio, Bristol-Myers Squibb, Celgene, GSK, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Seagen, Takeda

University College London Hospitals NHS Foundation Trust, London, UK

Dr Rakesh Popat is an Associate Professor at University College London and Consultant Haematologist at University College London Hospitals with an interest in multiple myeloma.

He graduated from Guy’s and St. Thomas’ Medical School in London and trained in haematology at St. Bartholomew’s and the Royal London Hospitals. During this time he completed a PhD in novel treatments for myeloma and was awarded a fellowship to attend the Dana Farber Cancer Institute, Boston USA as part of this.

He has particular experience with novel treatments including immunotherapies such as CAR-T cell therapy and new antibody approaches. At University College Hospital, he leads the myeloma clinical trials programme, is the Cancer lead at the NIHR UCLH Clinical Research Facility and trials co-lead for the UCL Experimental Cancer Medicine Centre.

Dr Popat is the Chair of the UK Myeloma Research Alliance, NCRI Myeloma working group, is on the executive board of the UK Myeloma Society, the Young Board of the European Myeloma Network and a member of the International Myeloma Working Group. He is the Chief Investigator for a number of relapsed myeloma studies and the Principal Investigator for the NIHR Health Informatics Collaborative Myeloma database.

Research Support/P.I.: GSK
Consultant: GKS
Honoraria: Janssen, Abbvie, GSK, BMS, Pfizer, Sanofi
Scientific Advisory Board: Janssen, Abbvie, Roche
Travel/Meeting Attendance Support: Janssen


This program is targeted at Hematologists, oncologists, oncology nurses, and all other HCPs managing MM.

Educational grant

Independent symposium organized by Springer Healthcare IME. This program is made possible thanks to an educational grant received from GlaxoSmithKline.

healthcare professionals completing our programs
educational programs launched
countries receiving live education


Rebecca Cox

Principal Medical Education Writer

Related Programs |view all programs